title: [Tamsulosin in the treatment of patients with ureteroliths of the lower third of the ureter clinical and pharmacoeconomic grounds].
abstract: Alpha1-adrenoblocker tamsulosin reduces muscle spasm in the ureteric wall, decreases peristalsis below and raises pressure above the stone thus facilitating stone passage. Patients on tamsulosin had spontaneous stone passage in 73.8% cases while only 22.4% patients on routine therapy became stone free. Tamsulosin also shortens hospital stay. Use of tamsulosin 0.4 mg daily in patients with distal ureteric stones is pathogenetically validated, is highly clinically and cost effective.
authors.forename: V P
authors.initials: VP
authors.lastname: Avdoshin
authors.forename: M I
authors.initials: MI
authors.lastname: Andriukhin
authors.forename: M I
authors.initials: MI
authors.lastname: Barabash
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Taskinen
authors.forename: E V
authors.initials: EV
authors.lastname: Ol'shanskaia
authors.forename: P I
authors.initials: PI
authors.lastname: Motin
authors.forename: M
authors.initials: M
authors.lastname: Khaĭdar
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000191:economics* / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides / Q000191:economics* / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome; D014514:Ureteral Calculi / Q000188:drug therapy* / Q000191:economics
chemical_list: D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin